NCT00838578 - Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

October 31, 2012

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL

KRN330

KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.

DRUG

Irinotecan

Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.

Trial Locations (12)

NYU Clinical Trials Office, New York University Cancer Institute, New York

Greater Baltimore Medical Center, Baltimore

Emory University - Winship Cancer Institute, Atlanta

University of Florida COllege of Medicine/Shands Cancer Center, Gainesville

University of Miami - Sylvester Comprehensive Cancer Center, Miami

Florida Cancer Specialists, Fort Myers

Clearview Cancer Institute, Huntsville

Sarah Cannon Research Institute, Nashville

Vanderbilt University Medical Center, Nashville

Arizona Clinical Research Center, Tucson

USC/Norris Comprehensive Cancer Center, Los Angeles

Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington D.C.